4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Inclusion Criteria:

• ≥50 years of age at time of consent

• Treatment naïve MNV secondary to nAMD in the study eye

• Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflectivematerial, or leakage) identified by fluorescein angiography (FA) or spectral domainoptical coherence tomography (SD-OCT), in the study eye, at the Screening Visitconfirmed by the Reading Center

• Demonstrated clinical response to aflibercept and functional stability in the studyeye as confirmed by the Reading Center

• BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) inthe study eye at the Screening Visit

• CST less than or equal to 500 microns in the study eye at screening visit, confirmedby the central reading center

Exclusion Criteria:

Ocular Conditions:

• MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinalhemorrhage in the foveal central subfield (1 mm diameter))

• History of retinal detachment in the study eye

• History of or presence of active inflammation in either eye

• Glaucoma or intraocular hypertension requiring more than 2 topical medications forcontrol

Systemic Conditions and Considerations:

• Major illness or major surgical procedure in the 28 days prior to the ScreeningVisit

• Uncontrolled blood pressure

• Acute coronary syndrome, myocardial infarction or coronary artery revascularization,cerebrovascular accident, transient ischemic attack within 6 months of the ScreeningVisit

• History of autoimmune condition that may predispose to the development of uveitis